Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Apr 28;12(4):701-704.
doi: 10.21037/tcr-23-192. Epub 2023 Apr 4.

Combining immunotherapy and radiotherapy in hepatocellular carcinoma: the importance of irradiated tumor burden and the possible role of a low dose radiotherapy induction strategy

Clemens Grassberger  1 , Gentry King  2 , Smith Apisarnthanarax  1
Affiliations
Editorial

Combining immunotherapy and radiotherapy in hepatocellular carcinoma: the importance of irradiated tumor burden and the possible role of a low dose radiotherapy induction strategy

Clemens Grassberger et al. Transl Cancer Res. .
No abstract available

Keywords: Hepatocellular carcinoma (HCC); checkpoint inhibition; combination therapy; radiotherapy (RT); tumor burden.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-23-192/coif). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Tumor control probability (full lines, right axis) and surviving fraction of initial tumor burden (dashed lines, left axis) for a very radioresistant patient (red) and one of average radioresistance (blue). Prescribed dose based on a 5-fraction regimen with varying per fraction dose, no re-population was assumed during the 5-fraction treatment.
See this image and copyright information in PMC

Comment on

References

    1. Juloori A, Katipally RR, Lemons JM, et al. Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2023;115:202-13. 10.1016/j.ijrobp.2022.09.052 - DOI - PubMed
    1. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502. 10.1016/S0140-6736(17)31046-2 - DOI - PMC - PubMed
    1. Mushti SL, Mulkey F, Sridhara R. Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials. Clin Cancer Res 2018;24:2268-75. 10.1158/1078-0432.CCR-17-1902 - DOI - PubMed
    1. Kim N, Cheng J, Huang WY, et al. Dose-Response Relationship in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: A Pooled Analysis of an Asian Liver Radiation Therapy Group Study. Int J Radiat Oncol Biol Phys 2021;109:464-73. 10.1016/j.ijrobp.2020.09.038 - DOI - PubMed
    1. Huang AC, Postow MA, Orlowski RJ, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 2017;545:60-5. 10.1038/nature22079 - DOI - PMC - PubMed